- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07526896
Verbetering van klinische resultaten bij hartfalen door gebruik van het defibrillatie-elektrode implantaatsysteem voor linker bundeltakgebiedstimulatie (ACHIEVED LBBAP)
Verbetering van klinische uitkomsten bij hartfalen door gebruik van defibrillatie-elektrode implantaatsysteem voor linker bundeltakgebied pacing
This 2x2 randomized crossover feasibility study will evaluate the therapeutic value of adding pacing from the left ventricular lead to Left Bundle Branch Area Pacing (LBBAP) using a cardiac resynchronization therapy defibrillator (CRT-D). This combined therapy is known as Left Bundle Branch Optimized Cardiac Resynchronization Therapy (LOT-CRT) and will be compared to LBBAP therapy over sequential 6-month periods in CRT-indicated patients with LBBB. Primary and secondary outcomes are echocardiographic changes. Exploratory assessments will include NT-proBNP and subject-reported quality of life (KCCQ). An observational treatment arm will include subjects who have not been randomized due to unsuccessful implant for real-world observational analysis
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Robert Stadler
- Telefoonnummer: 763-526-0261
- E-mail: robert.stadler@medtronic.com
Studie Locaties
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Werving
- Minneapolis Heart Institute Foundation
-
Hoofdonderzoeker:
- John Zakaib
-
Contact:
- Ellen Thomas
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subject meets current ACC/AHA/HRS guidelines for implantation of a CRT-D device.
- Subject has documented LVEF ≤ 35% within 60 days of enrollment.
- Subject meets the criteria for presence of Strauss-defined LBBB.
- Subject meets NYHA classification II or III.
- Subject is willing and able to provide written consent.
- Subject is at least 18 years of age at the time of consent.
- Subject is geographically stable and willing and able to complete study procedures, including follow-up visits.
- The subject's medical records must be accessible by the enrolling site over the follow-up period.
Exclusion Criteria:
- Subject has documented myocardial infarction before enrollment.
- Subject has non-LBBB conduction patterns such as Right Bundle Branch Block (RBBB) or non-specific IVCD.
- Subject has 2nd or 3rd degree AV block.
- Subject has persistent or permanent atrial fibrillation (AF) or atrial flutter (AFL).
- Subject has intrinsic (non-paced) QRS duration ≤ 120ms.
- Subject with previous or existing pacemaker (including transvenous and transcatheter pacing system), Implantable Cardioverter Defibrillator (ICD, transvenous) or CRT-D (transvenous) device or leads.
- Subject has contraindications for screw-in transvenous lead placement (e.g., mechanical right heart valve).
- Subject underwent valve surgery within 90 days prior to enrollment.
- Subject is unable or unwilling to undergo baseline CMR imaging, if previously collected CMR images are unavailable or do not meet minimum acceptable criteria.
- Subject is post-heart transplantation or is actively listed on the transplantation list.
- Subject is implanted with a left ventricular assist device (LVAD).
- Subject has severe renal disease.
- Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure.
- Subject has complex and uncorrected congenital heart disease.
- Subject has life expectancy of less than 12 months.
- Subject is pregnant or breastfeeding.
- Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Observational Treatment Arm
|
CRT-D programmed for LOT-CRT (LBBAP + LV lead ON) ICD programmed for LBBAP |
|
Experimenteel: Sequence 1
LBBAP therapy for 6 months followed by LOT-CRT for 6 months |
CRT-D programmed for LBBAP (LV lead OFF) CRT-D programmed for LOT-CRT (LBBAP + LV lead ON) |
|
Experimenteel: Sequence 2
LOT-CRT for 6 months followed by LBBAP therapy for 6 months |
CRT-D programmed for LBBAP (LV lead OFF) CRT-D programmed for LOT-CRT (LBBAP + LV lead ON) |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Left ventricular ejection fraction (LVEF)
Tijdsspanne: Baseline, 6 months, 12 months
|
Change in LVEF assessed by echocardiography during each therapy period (baseline to 6 months, 6 months to 12 months). |
Baseline, 6 months, 12 months
|
|
Left ventricular end-systolic volume (LVESV)
Tijdsspanne: Baseline, 6 months, 12 months
|
Change in LVESV assessed by echocardiography during each therapy period (baseline to 6 months, 6 months to 12 months). |
Baseline, 6 months, 12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Left ventricular ejection fraction (LVEF)
Tijdsspanne: Baseline, 6 months
|
Change in LVEF assessed by echocardiography from baseline to 6 months |
Baseline, 6 months
|
|
Left ventricular end-systolic volume (LVESV)
Tijdsspanne: Baseline, 6 months
|
Change in LVESV assessed by echocardiography from baseline to 6 months. |
Baseline, 6 months
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MDT25031
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .